Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Halted 12-12 16:00:00 EST

0.0743

+0.0026

+3.63%

盘后0.0779

+0.0036+4.85%

19:49 EST

High0.0800	Low0.0716	Vol11.47M
Open0.0790	D1 Closing0.0717	Amplitude11.72%
Mkt Cap4.46M	Tradable Cap3.71M	Total Shares59.99M
T/O874.83K	T/O Rate22.97%	Tradable Shares49.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":0.0743,"timestamp":1765573200000,"preClose":0.0717,"halted":3,"volume":11472082,"hourTrading":{"tag":"盘后","latestPrice":0.0779,"preClose":0.0743,"latestTime":"19:49 EST","volume":782289,"amount":59959.3003,"timestamp":1765586998482},"delay":0,"floatShares":49938674,"shares":59991852,"eps":-0.855967,"marketStatus":"Halted","change":0.0026,"latestTime":"12-12 16:00:00 EST","open":0.079,"high":0.08,"low":0.0716,"amount":874828.04844466,"amplitude":0.117155,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.855967,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":0.0717,"preHourTrading":{"tag":"盘前","latestPrice":0.0747,"preClose":0.0717,"latestTime":"09:29 EST","volume":2462441,"amount":185112.613358276,"timestamp":1765549790273},"postHourTrading":{"tag":"盘后","latestPrice":0.0779,"preClose":0.0743,"latestTime":"19:49 EST","volume":782289,"amount":59959.3003,"timestamp":1765586998482},"volumeRatio":1.1775372256172842},"requestUrl":"/m/hq/s/CMND/wiki","defaultTab":"wiki","newsList":[{"id":"2590036855","title":"Clearmind Medicine Regains Nasdaq Compliance Amid Equity Rule Scrutiny","url":"https://stock-news.laohu8.com/highlight/detail?id=2590036855","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590036855?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:32","pubTimestamp":1765539132,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. recently addressed a regulatory issue related to Nasdaq's Minimum Stockholders' Equity Rule, which requires listed companies to maintain at least $2,500,000 in stockholders' equity. The company received notification from Nasdaq confirming it had regained compliance with this rule. However, Nasdaq will continue to monitor Clearmind Medicine's compliance, and failure to meet the requirement in future periodic reports could result in delisting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire  on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL50pZXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014039.USD","CMND","BK4585","SG9999014005.SGD","SG9999014021.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","BK4007","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2590503524","title":"Clearmind Medicine Successfully Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503524","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503524?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:32","pubTimestamp":1765539120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA99RGQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2590558058","title":"Clearmind Medicine Announces 1-for-40 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558058","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558058?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:15","pubTimestamp":1765401312,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced a 1-for-40 reverse share split of its common shares, effective December 15, 2025. This move aims to help the company regain compliance with Nasdaq's minimum bid price requirement. After the reverse split, the number of outstanding common shares will be reduced from approximately 60 million to about 1.5 million, with fractional shares rounded up to the nearest whole share. The company's authorized share capital remains unchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire  on December 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL9JFRzG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4112","BK4588","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","BK4585","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","SG9999014013.SGD","SG9999014039.USD","CMND","BK4007","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2589488058","title":"Clearmind Medicine Faces Nasdaq Delisting Risk Over Sub-$1 Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2589488058","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589488058?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:00","pubTimestamp":1764972011,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has received notice from the Nasdaq Stock Market that it is not in compliance with the minimum bid price requirement, as its common shares have traded below $1.00 for 30 consecutive business days. The company has until June 2, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Failure to meet this requirement could result in the delisting of its shares from Nasdaq. The company is evaluating its options to address the issue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire  on December 05, 2025, and is solely responsible for the information containe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL6mNrQx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","CMND","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","BK4007","NDAQ","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2588469090","title":"BRIEF-Clearmind Medicine Inc Files For Offering Of Up To 16 Million Common Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588469090","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588469090?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:51","pubTimestamp":1764766261,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Inc Files For Offering Of Up To 16 Million Common Shares - SEC FilingDec 3  - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE INC FILES FOR OFFERING OF UP TO 16 MILLION COMMON SHARES - SEC FILINGSource text: [ID:n0001213900-25-117534]Further company coverage: CMND.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X815M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2588056135","title":"BRIEF-Clearmind Medicine Advances Cmnd-100 To Dosing Phase At Hadassah Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056135","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056135?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:57","pubTimestamp":1764683859,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Advances Cmnd-100 To Dosing Phase At Hadassah Medical CenterDec 2 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE ADVANCES CMND-100 TO DOSING PHASE AT HADASSAH ME","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4F7YPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2588053511","title":"Clearmind Medicine Advances Cmnd-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/Iia Clinical Trial for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053511?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:57","pubTimestamp":1764680235,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4F7YPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2588847773","title":"Clearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588847773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588847773?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:56","pubTimestamp":1764597376,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary, non-hallucinogenic, MEAI-based oral therapy developed for Alcohol Use Disorder . The company reported positive top-line safety and efficacy results from the trial's first cohort of six participants, with dosing conducted at Johns Hopkins University School of Medicine and Yale School of Medicine. Following an unblinded interim safety review, the independent Data and Safety Monitoring Board  unanimously recommended that the trial proceed. Additionally, Clearmind has expanded its clinical network by initiating patient enrollment at Tel Aviv Sourasky Medical Center in Israel, joining other active sites in the multinational study. Results from the initial cohort have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL28dVVq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4588","LU2210150020.SGD","CMND","BK4007","LU0314104364.USD","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588738487","title":"Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full Dsmb Approval, and New Elite Site Joins the Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588738487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588738487?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:56","pubTimestamp":1764597360,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA7YZXQ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2587073748","title":"Clearmind Medicine Inc. Announces Date for Upcoming Annual General and Special Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2587073748","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587073748?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:05","pubTimestamp":1764363919,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced that it will hold its annual general and special meeting of shareholders virtually on December 29, 2025. During the meeting, shareholders will consider and vote on several resolutions, including the presentation of audited financial statements, fixing the number of directors, election of directors, appointment of an auditor, and approval of an omnibus equity incentive plan. The meeting will also address any further business that may properly come before the shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Se","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL2hdKnl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2586230426","title":"Why Did Clearmind Medicine Shares Jump 7% In Pre-Market Trading?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586230426","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586230426?lang=en_us&edition=fundamental","pubTime":"2025-11-26 17:32","pubTimestamp":1764149520,"startTime":"0","endTime":"0","summary":"Clearmind Medicine rose 7.09% in pre-market trading after announcing enrollment of first patient in trial for alcohol use disorder.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/26/Stock-Market-Growth-Vector-With-Green-Ca_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/26/Stock-Market-Growth-Vector-With-Green-Ca_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/49078425/why-did-clearmind-medicine-shares-jump-7-in-pre-market-trading","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/49078425/why-did-clearmind-medicine-shares-jump-7-in-pre-market-trading","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2586743420","title":"Clearmind Medicine Kicks-off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in Its in Phase I/Iia Alcohol Use Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2586743420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586743420?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:17","pubTimestamp":1764073020,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA3FZH4Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2585670724","title":"Clearmind says DSMB approves continuation of Phase I/IIa trial of CMND-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2585670724","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585670724?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:55","pubTimestamp":1763992515,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced that its independent Data and Safety Monitoring Board has completed a scheduled interim review of the Company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-says-dsmb-approves-continuation-of-phase-i-iia-trial-of-cmnd-100-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-says-dsmb-approves-continuation-of-phase-i-iia-trial-of-cmnd-100-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2585296467","title":"Clearmind Medicine Advances CMND-100 Clinical Trial After Positive Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2585296467","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585296467?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:51","pubTimestamp":1763992275,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced that its independent Data and Safety Monitoring Board  has unanimously recommended the continuation of its ongoing FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary, non-hallucinogenic neuroplastogen, in the treatment of Alcohol Use Disorder . The recommendation follows a scheduled interim review based on encouraging top-line data from the first cohort, which demonstrated a favorable safety profile, with no serious adverse events reported and good tolerability among participants. The multinational, multi-center trial is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100. The interim results have already been reviewed by the DSMB, supporting the continuation of the trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL8F88jL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","LU0314104364.USD","CMND","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2585146726","title":"Clearmind Medicine Inc - Dsmb Recommends Continuation of Cmnd-100 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2585146726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585146726?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:51","pubTimestamp":1763992260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA88VTZ2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2585005467","title":"Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2585005467","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585005467?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:51","pubTimestamp":1763992260,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, Nov.  24, 2025  (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on discovery and de","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193523/0/en/Clearmind-Medicine-s-Data-and-Safety-Monitoring-Board-Unanimously-Approves-Continuation-of-Phase-I-IIa-Clinical-Trial-for-CMND-100-Following-Positive-Interim-Safety-Review.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2584380011","title":"Clearmind Medicine Expands FDA-Approved Alcohol Use Disorder Trial to Hadassah Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2584380011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584380011?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:01","pubTimestamp":1763636475,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced the initiation of its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral drug candidate targeting Alcohol Use Disorder , at Hadassah Medical Center in Jerusalem, Israel. This addition brings the total number of global trial sites to five, including Yale, Johns Hopkins, Tel Aviv Sourasky, and IMCA. The multinational, multi-center study is designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD. Top-line data from the first cohort have already been presented, demonstrating a favorable safety profile, strong treatment observance, and high adherence to the dosing regimen, with no serious adverse events reported. The study is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL1lFRjY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","BK4007","BK4588","CMND","BK4585","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD"],"gpt_icon":0},{"id":"2584413801","title":"Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2584413801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584413801?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:01","pubTimestamp":1763636460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA5GTCJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2584948540","title":"Clearmind Medicine- Entered Securities Purchase Agreement for Purchase & Sale of 10,925,000 of Co’s Common Shares in Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2584948540","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584948540?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:11","pubTimestamp":1763550681,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2584442958","title":"Clearmind Medicine Reports Positive Early Results for Alcohol Use Disorder Drug in Phase I/IIa Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584442958","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584442958?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:56","pubTimestamp":1763474173,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder . The trial is being conducted at Johns Hopkins University School of Medicine and Yale School of Medicine's Department of Psychiatry. The initial data indicate that CMND-100 demonstrated a favorable safety profile, with no serious adverse events reported and high adherence to the dosing regimen among participants. These results have already been presented by the company and support the ongoing evaluation of CMND-100 as a potential therapy for AUD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL6MkFYk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","LU0314104364.USD","BK4007","LU2095319765.USD","LU2210150020.SGD","CMND"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":-0.4245},{"period":"1month","weight":-0.7606},{"period":"3month","weight":-0.9272},{"period":"6month","weight":-0.9135},{"period":"1year","weight":-0.9491},{"period":"ytd","weight":-0.9462}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.120452},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.046234},{"month":3,"riseRate":0,"avgChangeRate":-0.347646},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.169588},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.01702},{"month":6,"riseRate":0.333333,"avgChangeRate":0.080414},{"month":7,"riseRate":0.333333,"avgChangeRate":0.008507},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.088917},{"month":9,"riseRate":0,"avgChangeRate":-0.22938},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.209618}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction